[go: up one dir, main page]

WO2023062365A3 - Lentiviral vectors - Google Patents

Lentiviral vectors Download PDF

Info

Publication number
WO2023062365A3
WO2023062365A3 PCT/GB2022/052584 GB2022052584W WO2023062365A3 WO 2023062365 A3 WO2023062365 A3 WO 2023062365A3 GB 2022052584 W GB2022052584 W GB 2022052584W WO 2023062365 A3 WO2023062365 A3 WO 2023062365A3
Authority
WO
WIPO (PCT)
Prior art keywords
ltr
modified
vector genome
lentiviral vector
polyadenylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2022/052584
Other languages
French (fr)
Other versions
WO2023062365A2 (en
Inventor
Daniel Farley
Jordan Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Publication of WO2023062365A2 publication Critical patent/WO2023062365A2/en
Publication of WO2023062365A3 publication Critical patent/WO2023062365A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/007—Vectors comprising a special origin of replication system tissue or cell-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C12N2840/445—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor for trans-splicing, e.g. polypyrimidine tract, branch point splicing

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to the production of lentiviral vectors. More specifically, the present invention relates to a nucleotide sequence encoding a lentiviral vector genome, wherein the 3' LTR of the lentiviral vector genome comprises a modified polyadenylation sequence, and wherein the modified polyadenylation sequence comprises a polyadenylation signal which is 5' of the 3' LTR R region. The invention also relates to a nucleotide sequence encoding a lentiviral vector genome, wherein the lentiviral vector genome comprises a modified 5' LTR, and wherein the R region of the modified 5' LTR comprises at least one polyadenylation downstream enhancer element (DSE). Methods and uses of such nucleotide sequences are also encompassed by the invention.
PCT/GB2022/052584 2021-10-12 2022-10-12 Lentiviral vectors Ceased WO2023062365A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2114532.1A GB202114532D0 (en) 2021-10-12 2021-10-12 Lentiviral Vectors
GB2114532.1 2021-10-12

Publications (2)

Publication Number Publication Date
WO2023062365A2 WO2023062365A2 (en) 2023-04-20
WO2023062365A3 true WO2023062365A3 (en) 2023-05-19

Family

ID=78595017

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2022/052584 Ceased WO2023062365A2 (en) 2021-10-12 2022-10-12 Lentiviral vectors

Country Status (2)

Country Link
GB (1) GB202114532D0 (en)
WO (1) WO2023062365A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116804187A (en) * 2023-07-24 2023-09-26 中国农业科学院兰州兽医研究所 A replication-deficient foot-and-mouth disease virus, construction method and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044458A2 (en) * 1999-12-14 2001-06-21 Novartis Ag Bovine immunodeficiency virus (biv) based vectors
US8642570B2 (en) * 2009-05-15 2014-02-04 Medizinische Hochschule Hannover ASLV vector system

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512421A (en) 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
DE69729007T2 (en) 1996-08-07 2005-04-07 Darwin Discovery Ltd., Slough HYDROXAMIC ACID AND CARBOXYLIC DERIVATIVES WITH MMP AND TNF HEMMENDER EFFECT
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
PT904392E (en) 1996-10-17 2001-06-29 Oxford Biomedica Ltd RETROVIRAL VECTORS
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
CA2315269A1 (en) 1997-12-22 1999-07-01 Oxford Biomedica (Uk) Limited Equine infectious anaemia virus (eiav) based
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
GB9904905D0 (en) 1999-03-03 1999-04-28 Oxford Biomedica Ltd Cells
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
AU2001258668A1 (en) 2000-05-12 2001-11-20 University Of Southern California Retroviral vectors comprising an enhanced 3' transcription termination structure
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
EP1504108B1 (en) 2002-02-01 2013-04-17 Oxford Biomedica (UK) Limited Lentiviral vector
AU2003260769A1 (en) 2002-09-03 2004-03-29 Oxford Biomedica (Uk) Limited Retroviral vector and stable packaging cell lines
WO2005056057A1 (en) 2003-12-04 2005-06-23 Childrens Hospital Los Angeles Research Institute Minimal lentiviral vector system
FR2872170B1 (en) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse NON-INTERACTIVE AND NON-REPLICATIVE LENTIVIRUS, PREPARATION AND USES
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
EP3192874B1 (en) 2008-06-18 2019-10-16 Oxford BioMedica (UK) Limited Virus purification
US20110294114A1 (en) 2009-12-04 2011-12-01 Cincinnati Children's Hospital Medical Center Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
FI3633040T3 (en) 2017-12-22 2023-08-03 Oxford Biomedica Ltd RETROVIRUS VECTOR
US20220348958A1 (en) 2019-07-23 2022-11-03 Oxford Biomedica (Uk) Limited Enhancing Production of Lentiviral Vectors
WO2021094752A1 (en) 2019-11-12 2021-05-20 Oxford Biomedica (Uk) Limited Production system
US20240052366A1 (en) 2020-02-13 2024-02-15 Oxford Biomedica (Uk) Limited Production of Lentiviral Vectors
WO2021181108A1 (en) 2020-03-13 2021-09-16 Oxford Biomedica (Uk) Limited Lentiviral vectors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044458A2 (en) * 1999-12-14 2001-06-21 Novartis Ag Bovine immunodeficiency virus (biv) based vectors
US8642570B2 (en) * 2009-05-15 2014-02-04 Medizinische Hochschule Hannover ASLV vector system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MICHAEL D MÜHLEBACH ET AL: "Chapter 13: Gammaretroviral and Lentiviral Vectors for Gene Delivery", 1 January 2010, RETROVIRUSES: MOLECULAR BIOLOGY, GENOMICS AND PATHOGENESIS, CAISTER ACADEMIC PRESS, PAGE(S) 347 - 370, ISBN: 978-1-912530-97-7, XP009536782 *

Also Published As

Publication number Publication date
GB202114532D0 (en) 2021-11-24
WO2023062365A2 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
WO2023062365A3 (en) Lentiviral vectors
Sakaue et al. Oxidation of aromatic amines with hydrogen peroxide catalyzed by cetylpyridinium heteropolyoxometalates
MX2022016101A (en) Vector.
ATE326541T1 (en) LENTIVIRAL VECTORS FOR THE PRODUCTION OF IMMUNOTHERAPEUTIC COMPOSITIONS
WO2002028891A3 (en) Listeria inocua, genome and applications
Faria et al. Emergence and adaptation of the cellular machinery directing antigenic variation in the African trypanosome
JP7358379B2 (en) Improving the conversion of taurine to alkyltaurate amides using phosphoric acid catalysts
DK1085094T3 (en) Nucleotide sequences encoding the dapF gene
EP4407026A3 (en) Variants of terminal deoxynucleotidyl transferase and uses thereof
JP5826964B1 (en) Method for producing pyridine-3-sulfonyl chloride
WO2019235782A8 (en) Novel streptococcus suis bacteriophage str-sup-2, and use thereof for inhibiting proliferation of streptococcus suis strains
EA200500897A1 (en) METHOD OF OBTAINING PETROPHENONS
JPS62108861A (en) Production of lactam having 8-15 carbon atoms
KR20010062688A (en) Method for Producing 2-Alkyl-4-Isothiazoline-3-One
SE441524B (en) SOLID SODIUM OR POTASSIUM P-HYDROXIMANDELATE MONOHYDRATE AND SET FOR ITS PREPARATION
WO2022010860A3 (en) Infectious recombinant vesicular stomatitis virus (rvsv) bearing the spike glycoprotein s of sars-cov-2 and uses thereof
WO2012018114A1 (en) Method for producing epoxy compound by oxidation
WO2002092825A3 (en) Retroviral vectors for gene therapy
JP2000026406A (en) Production of di-ter-peroxides
JP7227711B2 (en) Method for producing 2-(2-haloethyl)-1,3-dioxolane
CN106497137B (en) A kind of preparation method of disperse yellow dye N- (dinitrophenyl group) p-phenylenediamine
AU2024249959A1 (en) Trem compositions and methods of use
AU2024233847A1 (en) Process for the synthesis of (s)-edelfosine or (r)-edelfosine
JPS60172963A (en) Production of 2,2,6,6-tetramethyl-4-oxopiperidine
WO2024145426A3 (en) Omni-335 crispr nuclease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22792878

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22792878

Country of ref document: EP

Kind code of ref document: A2